IP Library Patent Application 13548122
Patent Application
App. No. 13/548,122

VASCULAR THERAPEUTICS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/548,122
Abstract

The present invention provides a method of preventing or reducing restenosis, neointima formation, graft failure, atherosclerosis, angiogenesis and/or solid tumour growth in a subject. The method comprises administering to the subject a prophylactically effective dose of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or nuclear accumulation or activity of c-Jun. It is preferred that the nucleic acid is a DNAzyme that targets c-Jun mRNA.

Claims (20)

1 - 2 . (canceled)

3 . A method of treating or inhibiting solid tumor growth in a subject, the method comprising administering to a subject an effective dose of a a DNAzyme targeted against c-Jun, wherein the DNAzyme comprises:

(i) a catalytic domain which cleaves mRNA at a purine:pyrimidine cleavage site;

(ii) first binding domain contiguous with the 5′ end of the catalytic domain; and

(iii) a second binding domain contiguous with the 3′ end of the catalytic domain; wherein the binding domains are sufficiently complementary to two regions immediately flanking a purine:pyrimidine cleavage site within the c-Jun mRNA such that the DNAzyme cleaves the c-Jun mRNA.

4 . (canceled)

5 . The method according to claim 3 , wherein the solid tumor growth is melanoma.

6 - 10 . (canceled)

11 . The method according to claim 3 , wherein both binding domains have a combined total length of at least 14 nucleotides.

12 . The method according to claim 3 , wherein the binding domain lengths are 9 nucleotides.

13 . The method according to claim 3 , wherein the catalytic domain has a nucleotide sequence GGCTAGCTACAACGA.

14 . (canceled)

15 . The method according to claim 3 , wherein the DNAzyme cleaves c-Jun mRNA in the region from residues U1296 to G1497.

16 . The method according to claim 3 , wherein the cleavage site is the GU site corresponding to nucleotides 1311-1312 of SEQ ID NO:1.

17 . (canceled)

18 . The method according to claim 3 , wherein the DNAzyme incorporates a 3′-3′ inversion at one or more termini.

19 - 40 . (canceled)

41 . A method of treating or inhibiting solid tumor growth in a subject, the method comprising administering to the subject an effective dose of a DNAzyme targeted against c-Jun, wherein the DNAzyme has the sequence of SEQ ID NO:5.

42 . The method according to claim 41 , wherein the solid tumor growth is melanoma.

43 . The method according to claim 41 , wherein the DNAzyme incorporates a 3′-3′ inversion at one or more termini.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2012
From: KHACHIGIAN, LEVON M.
To: UNISEARCH LIMITED
Reel/Frame 029283/0267 →
CHANGE OF NAME Recorded Nov 12, 2012
From: UNISEARCH LTD
To: NEWSOUTH INNOVATIONS PTY LIMITED
Reel/Frame 029283/0277 →